-
公开(公告)号：EP1967212B1
公开(公告)日：2016-09-21
申请号：EP06817995.1
申请日：2006-11-20
发明人： RAMÓN HERNÁNDEZ, José, Ángel , CASTRO ODIO,Fidel, Raúl , SÁEZ MARTÍNEZ, Vivian, María , PÁEZ MEIRELES, Rolando , FERNÁNDEZ SÁNCHEZ, Eduardo
CPC分类号： A61K47/60
-
2.发明授权COMBINATIONS OF GROWTH- AND HORMONE-REGULATING FACTORS FOR THE TREATMENT OF NEOPLASIA 有权COMBINING生长激素，并引导因素，治疗肿瘤
公开(公告)号：EP1576965B1
公开(公告)日：2009-10-14
申请号：EP03767380.3
申请日：2003-12-22
发明人： BOVER FUENTES, Eddy , BASULTO BAKER, R., Sociedad Patriotica, 6A entre , PIMENTEL VAZQUEZ, Eulogio , JUNCO BARRANCO, Jesus , FUENTES AGUILAR, Franklin , ARTEAGA MORE , Niurka , CALZADA AGUILERA, Lesvia , HERNANDEZ DOMINGUEZ, Héctor , Lopez Saez, Yovisleidys , GUILLEN NIETO, Gerardo, Enrique , Chinea Santiago, Glay
IPC分类号： A61K39/00 , A61K39/395
CPC分类号： A61K39/0011 , A61K39/395 , A61K2039/6037 , A61K2039/6068 , A61K2039/6081
摘要： The invention relates to the field of immunology, endocrinology and oncology and, in particular, the generation of a combined immune response to determined growth and hormone factors. A synergic effect, outlined herein, between factors regulating growth (EGF, TGF, VEGF) and hormones involved in the sexual hormone release cascade or reproduction (GnRH, LH, FSH) stimulates the anti-tumour response which is expressed as a reduction in the tumour mass and an increase in the survival time.
-
公开(公告)号：EP1801119B1
公开(公告)日：2009-06-24
申请号：EP05779505.6
申请日：2005-09-16
发明人： SANTOS SAVIO, Alicia , CABRALES RICO, Ania , REYES ACOSTA, Osvaldo , GERONIMO PEREZ, Haydee , ARRIETA AGÜERO, Celia A. , PEREA RODRIGUEZ, Silvio, Ernesto
CPC分类号： C07K14/5443 , A61K38/00 , A61K39/00 , C07K16/244
-
公开(公告)号：EP1550457B1
公开(公告)日：2008-12-31
申请号：EP03757652.7
申请日：2003-10-08
发明人： SANTOS SAVIO, Alicia , SILVA RODR GUEZ, Ricardo , MORERA DIAZ, Yanelis , RODR GUEZ ALFONSO, Armando, Alexei , MART NEZ CASTILLO, José, Rafael , GER NIMO P REZ, Haydee , MORO SORIA, Alejandro , PEREA RODR GUEZ, Silvio, Ernesto
CPC分类号： A61K39/0005
摘要： The invention relates to a vaccine composition comprising IL-15, which is used for active immunisation in the treatment of diseases associated with overexpression of said cytokine. The technical objective of the invention is the inhibition of the activity of IL-15 through the development of a therapeutic vaccine which generates IL-15-neutralising antibodies in the immunised individual. In the inventive vaccine composition, IL-15 can appear alone or coupled to a carrier protein, such as P64k, and an adjuvant, such as aluminium hydroxide. The invention also relates to the use of said vaccine in the treatment of rheumatoid arthritis and other diseases associated with overexpression of IL-15 or diseases in which said cytokine acts as a growth factor, such as in the case of leukemias.
-
5.发明公开Method for the identification and relative quantification of proteins based on the selective isolation of RRNK peptides for the simplification of complex mixtures of proteins 审中-公开基于肽的选择性分离的蛋白质的鉴定和相对定量方法PRNK对于复杂的蛋白质混合物的简化
公开(公告)号：EP1795896A3
公开(公告)日：2007-06-27
申请号：EP06077074.0
申请日：2006-11-22
发明人： Puente, Aniel Sanchez , Gonzalez Lopez, Luis Javier , Gil Valdés, Jeonvanis , Betancourt Nunez, Lazaro Hiram , Besada Pérez, Vladimir Armando , Fernandez de Cossio Dorta-Duque, Jorge , Alvarez Gil, Félix Modesto , Padron Palomares, Gabriel Ramon , Gomez, Yassel Ramos
IPC分类号： G01N33/68
CPC分类号： G01N33/6848 , G01N33/6842
摘要： A method based on the selective isolation of peptides originated by the cleavage at the C-terminal end of the arginine residues and do not possess lysine inside their sequences (péptidos RRnK), is described. The method is based on the blocking of amino groups of the LEP peptides and the separation of the RRnK peptides and the modified peptides by using a chromatography column or a chemical reaction of the modified peptides with a solid support. The method simplifies the complex mixtures of peptides by isolating selectively an average of 4 peptides/protein and it guarantees a coverage of 88% of the proteomes, its specificity and selectivity are very high (>95%), it is compatible with different types of isotopic labeling ( 13 C, 18 O or 15 N) and it is useful for the determination of the differential expression of proteins without the necessity of using the two-dimensional electrophoresis.
-
6.发明公开SPECIFIC ANTIBODY FRAGMENTS FOR THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA) 有权SPEZIFISCHEANTIKÖRPERFRAGMENTEFÜRDAS人类癌细胞抗原（CEA）
公开(公告)号：EP1505076A2
公开(公告)日：2005-02-09
申请号：EP03720119.1
申请日：2003-04-28
发明人： Gavilondo Cowley, Jorge Victor , Ayala Vila, Marta, C/ 186, No. 3117 Apto 3D e/ , Freyre Almeida Freya, de los Milagros , Acevedo Castro, Boris E., Calle Segunda , Bell Garcia, Hanssel, C/62 00906, 2do piso, apt 16 , Roque Navarro, Lourdes Tatiana , GonzaLez Lopez, Luis Javier, Calle 186, 003115 , Cremata Alvarez, José Alberto, Ave 31 No. 18207 , Montesino Segui, Raquel, Calle 184 No. 3112
CPC分类号： C07K14/22 , C07K16/3007 , C07K2317/622 , C07K2317/626
摘要： The invention refers to mono- and divalent (diabody) single chain Fv (scFv) antibody fragments, obtained by recombinant DNA techniques from the anti-carcinoembryonic antigen (CEA) monoclonal antibody (Mab) CB/ior-CEA.1. This antibody has high affinity for CEA and is employed in the diagnosis and follow-up of human colorectal tumors. As the original Mab, the monovalent fragment and the diabody exhibit high affinity for human CEA and recognize an epitope dependent of carbohydrate conservation. The monovalent scFv fragment and the diabody have affinity constants for CEA of (5.0 ± 0.4) x 10 9 L mol -1 and (2.8 ± 0.3) x 10 10 L mol -1 , respectively. These two fragments do not show cross reactivity with human normal cells and tissues, exception made of the normal colonic mucosa, where CEA is occasionally present. The fragments can be produced through the expression in recombinant microorganisms, starting from the cloning of the encoding variable region nucleic acid sequences obtained from the hybridoma that produces Mab CB/ior-CEA.1. As the original Mab, the monovalent scFv and the diabody have the ability to identify in vivo cells that produce human CEA and grow as tumors in mice. The monovalent scFv and the diabody have a molecular size 5 and 2.5 times lower, respectively, than the mouse Mab, and do not have Fc domains, fact this that confers them the potential to better penetrate tissues in vivo and to be less immunogenic in man.
摘要翻译： 本发明涉及通过来自抗癌胚抗原（CEA）单克隆抗体（Mab）CB / i-CEA.1的重组DNA技术获得的单价和二价（双抗体）单链Fv（scFv）抗体片段。 该抗体对CEA具有高亲和力，用于诊断和追踪人结肠直肠肿瘤。 作为原始的Mab，单价片段和双抗体对人CEA表现出高亲和力，并识别依赖于碳水化合物保护的表位。 单价scFv片段和双抗体对（5.0 +/- 0.4）×10 -9 L mol -1和（2.8 +/- 0.3）×10 10 L mol -1的CEA具有亲和力常数 ， 分别。 这两个片段不显示与人正常细胞和组织的交叉反应性，例外是正常结肠粘膜，其中CEA偶尔存在。 通过从产生Mab CB / i-CEA.1的杂交瘤获得的编码可变区核酸序列的克隆开始，可以通过重组微生物中的表达产生片段。 作为原始的Mab，单价scFv和双抗体具有鉴定产生人CEA的体内细胞并在小鼠中作为肿瘤生长的能力。 单价scFv和双抗体分别具有比小鼠Mab低5和2.5倍的分子量，并且不具有Fc结构域，事实上，这赋予它们在体内更好地渗透组织的潜力并且在人中具有较少的免疫原性 。
-
公开(公告)号：EP1356733A2
公开(公告)日：2003-10-29
申请号：EP01272600.6
申请日：2001-12-17
发明人： MENA CAMPOS, Jesus , PIMENTEL VAZQUEZ, Eulogio , HERNANDEZ GARCIA, Armando, Tomas , VELOZ GONZALES, Liuven , MARIN BRUZOS, Marieta , COMPTE ALBERTO, Oscar , DOMINGO PUENTE, Marilin , LEON BARRERAS, Licette , PUJOL FERRERO, Merardo , MENCHO PONCE, Juan, Diego , BORROTO NORDELO, Carlos
CPC分类号： A01N63/00 , A01N63/02 , A01N2300/00
摘要： This invention relates to pesticide and antiparasitic compositions for the control of pests, diseases and parasites attacking plants and animals. The compositions include, at least one chitinolytic agent or a chitinolytic activity-inducing agent, and sulfide or a sulfide-producing agent from microorganisms or chemical compounds, wherein the chitinolytic agent or the chitinolytic activity-inducing agent and sulfur or a sulfur-producing agent obtaining from microorganisms or chemical compounds are concurrently applied at a range significantly lower than any of the above-mentioned compounds, when they are individually to attain effective control.
摘要翻译： 本发明涉及用于防治害虫，疾病和寄生虫攻击植物和动物的农药和抗寄生虫剂组合物。 所述组合物包括至少一种chitinotictic试剂或chitinolytic活性诱导剂，以及来自微生物或化学化合物的硫化物或硫化物生成剂，其中所述chitinotictic试剂或所述chitinolytic活性诱导剂和硫或硫产生剂 当单独获得有效控制时，从微生物或化合物获得的同时应用于显着低于任何上述化合物的范围。
-
8.发明公开METHOD FOR OBTAINING ANTIGENIC STRUCTURES ENHANCING SPECIFIC CROSS REACTIVITY 审中-公开方法，抗菌素ZU ERHALTEN，WELCHE SPEZIFISCHEKREUZREAKTIVITÄTVERSTÄRKEN（15.05.02）
公开(公告)号：EP1334727A2
公开(公告)日：2003-08-13
申请号：EP01983427.4
申请日：2001-11-01
发明人： CRUZ RICONDO, Luis, Javier; , AGUILAR RUBIDO, Julio, César , IGLESIAS PEREZ, Enrique , REYES ACOSTA, Osvaldo , GARAY P REZ, Hilda, Elisa , MUZIO GONZ LEZ, Verena, Lucila , GUILL N NIETO, Gerardo Enrique , DUARTE CANO, Carlos , PENT N ARIAS, Eduardo
IPC分类号： A61K31/74 , A61K31/785 , A61K39/12 , A61K39/39 , A61K47/30 , A61K47/48 , C07K14/00 , C08G73/02
CPC分类号： A61K39/12 , A61K39/21 , A61K39/29 , A61K39/292 , A61K39/385 , A61K47/646 , A61K2039/545 , A61K2039/6031 , A61K2039/6075 , A61K2039/645 , C07K7/08 , C08G83/003 , C12N2730/10134 , C12N2740/16034 , C12N2770/24234 , Y02A50/386
摘要： The present invention is related to a method for obtaining antigenic structures with high cross reactivity, able to enhance the immune response to peptidic antigens administered systemically and/or mucosally, as well as with the chemical structures obtained from this method, and with formulations obtained and their uses.
The method described in the present invention enables the obtaining of new antigenic structures, starting from the selection and synthesis of dendrimers, which are coupled to carrier molecules. The resulting structures can be used adjuvated conveniently or in a formulation of various antigens. A synergistic effect can be found in the cross reactivity and immunogenicity. Furthermore, the formulations may contain stabilizers and preserves.
The antigenic structures of the present invention can be used in the pharmaceutical industry as vaccine formulations to prevent or to treat diseases in humans and animals, as well as in the development of diagnostic systems.摘要翻译： 本发明涉及一种用于获得具有高交叉反应性的抗原结构的方法，其能够增强对全身和/或粘膜施用的肽抗原的免疫应答，以及从该方法获得的化学结构，以及获得的制剂 他们的用途。 在本发明中描述的方法能够从与载体分子偶联的树枝状大分子的选择和合成开始获得新的抗原结构。 所得结构可以方便地或在各种抗原的制剂中使用。 在交叉反应性和免疫原性中可以发现协同效应。 此外，制剂可以含有稳定剂和防腐剂。 本发明的抗原结构可用于制药工业中作为预防或治疗人和动物疾病以及诊断系统开发中的疫苗制剂。
-
公开(公告)号：EP1029549A1
公开(公告)日：2000-08-23
申请号：EP99942707.3
申请日：1999-09-03
发明人： AGUILAR RUBIDO, Julio César , MUZIO GONZALEZ, Verena Lucila , GUILLEN NIETO, Gerardo Enrique , PENTON ARIAS, Eduardo , LEAL ANGULO, Maria de Jesús , PICHARDO DIAZ, Dagmara Calle 222 No. 2716 , IGLESIAS PEREZ, Enrique Edificio 25 Apto. 103 , HERRERA BUCH, Antonieta , SANDEZ OQUENDO, Bélquis , MUSACCHIO LASA, Alexis , QUINTANA VAZQUEZ, Diógenes , CROMBET MENENDEZ, Lissete
CPC分类号： A61K39/21 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K2039/53 , A61K2039/54 , A61K2039/543 , A61K2039/545 , A61K2039/55583 , C12N2740/16034
摘要： The present invention is related to the medical field, and in particular to the use of new formulations of adjuvants with vaccine antigens. The technical object of the invention is the development of formulations which are capable of potentiating the immune response of the organism to vaccines of nucleic acids. In order to attain this objective, a formulation has been developed which contains as fundamental components the vaccine nucleic acid and acemannan in adequate proportions, in addition to stabilizing and preservative agents. The formulations of the invention are applicable to the pharmaceutical industry as vaccine formulations both for human and animal use.
摘要翻译： 本发明涉及医疗领域，特别涉及使用具有疫苗抗原的佐剂的新制剂。 本发明的技术目的是开发能够增强生物体对核酸疫苗的免疫应答的制剂。 为了达到这个目标，除了稳定剂和防腐剂之外，已经开发出一种配方，其中含有足够比例的疫苗核酸和acemannan作为基本组分。 本发明的制剂适用于作为用于人类和动物使用的疫苗制剂的制药工业。
-
公开(公告)号：EP0971737A1
公开(公告)日：2000-01-19
申请号：EP98907815.9
申请日：1998-03-05
发明人： AGUILAR RUBIDO, Julio César , MUZIO GONZALEZ, Verena Lucila , LEAL ANGULO, Maria de Jesús , GUILLEN NIETO, Gerardo Enrique , PENTON ARIAS, Eduardo , VELIZ RIOS, Gloria , PICHARDO DIAZ, Dagmara , HERRERA BUCH, Antonieta , IGLESIAS PEREZ, Enrique , CRUZ RICONDO, Luis Javier , CARMENATE PORTILLA, Tania , MESA PARDILLO, Cirse , HECHAVARRIA GAY, Maydel , DIAZ MARTINEZ, Maylin , MADRAZO PINOL, Juan Joel
IPC分类号： A61K39/39 , A61K39/29 , A61K39/295
CPC分类号： A61K39/095 , A61K39/12 , A61K39/292 , A61K2039/54 , A61K2039/543 , A61K2039/55544 , A61K2039/55583 , A61K2039/55588 , C12N2730/10134 , Y10S514/885 , Y10S977/906
摘要： The present invention relates to the medical field, particularly to the use of new formulations of adjuvants as vaccinal antigenes. The technical objective of the present invention is precisely the development of formulations capable of raising and/or modulating the immune response of the organism to vaccinal antigenes at serum and mucus levels. In order to attain such objective, a formulation has been developed which contains as fundamental components the surface antigene of the B hepatitis virus and the acemanane in adequate proportions. As an extension of such result, formulations have been developed wherein: a) HBsAg is used as carrier of homologous and heterologous antigenes; b) systems for transmitting particulate antigens and c) soluble antigens, in combination with the acemanane in specific proportions. The formulations of this invention are applicable to the pharmaceutical industry as vaccinal formulations both for human and veterinary use.
-
-
-
-
-
-
-
-
-
搜索结果
76 条记录 (耗时 0.035 秒)
